Neovascular (Wet) Age-Related Macular Degeneration Clinical Trial
Official title:
A Phase 1/2 Dose-Escalation and Randomized, Controlled, Masked Expansion Trial of Intravitreal 4D-150 Gene Therapy in Adults With Neovascular (Wet) Age-Related Macular Degeneration
Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment
This Phase 1/2 trial is a prospective, multicenter, Phase 1/2 dose-escalation and randomized, controlled, masked expansion trial in adults with wet AMD undergoing active anti-VEGF treatment who have demonstrated a clinical response consistent with anti-VEGF activity. The trial consists of Dose Escalation, Dose Expansion, Steroid Optimization and Population Extension Cohorts. After receiving one time administration of 4D-150 by intravitreal injection, subjects will undergo assessments at monthly intervals for 24 months to assess safety and efficacy outcomes. Only subjects that received 4D-150 will then enter a long-term follow-up (LTFU) period to assess long-term safety of 4D-150 gene therapy and duration of clinical activity through year 5 (60 months). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04126317 -
Safety, Tolerability, and Efficacy of Aflibercept in Patients With Neovascular Age-Related Macular Degeneration
|
Phase 2 | |
| Completed |
NCT06184360 -
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
|
||
| Completed |
NCT04847895 -
Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications
|
||
| Active, not recruiting |
NCT05439629 -
Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration
|
Phase 3 | |
| Terminated |
NCT05473715 -
A Study to Learn How Well Aflibercept Injected Into the Eye Works and How Safe it is When Given in Customized Treatment Intervals in Patients With an Eye Disease Called Neovascular Age-related Macular Degeneration After Start of Treatment
|
Phase 4 | |
| Recruiting |
NCT06346600 -
A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
|